Core Viewpoint - Inhibikase Therapeutics is advancing its lead product IKT-001 into a late-stage clinical trial for pulmonary arterial hypertension (PAH), with plans to initiate a Phase 2b study in the second half of 2025, supported by a strengthened leadership team and refined study protocols [2][9]. Recent Developments - The company has appointed key executives, including Mark Iwicki as CEO and Chris Cabell as President and Head of Research & Development, to enhance its leadership team [9]. - Ongoing discussions with key opinion leaders are aimed at refining the study design for the upcoming Phase 2b clinical trial of IKT-001 [9]. - The company received a "Study May Proceed" letter for the Phase 2b trial in September 2024, indicating prior positive efficacy results from imatinib in PAH patients [9]. First Quarter 2025 Financial Results - The net loss for Q1 2025 was $13.7 million, or $0.15 per share, compared to a net loss of $4.6 million, or $0.73 per share in Q1 2024 [4][14]. - Research and development expenses increased to $10.5 million in Q1 2025 from $2.8 million in Q1 2024, including a non-cash charge of $7.4 million related to the acquisition of CorHepta [5]. - Selling, general and administrative expenses rose to $5.2 million in Q1 2025 from $2.0 million in Q1 2024 [6]. - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $93.2 million [6]. Balance Sheet Highlights - Total current assets as of March 31, 2025, were $94.2 million, a decrease from $98.6 million as of December 31, 2024 [12][13]. - Total liabilities were reported at $8.6 million as of March 31, 2025, compared to $3.7 million at the end of 2024 [13]. - Stockholders' equity decreased to $85.7 million as of March 31, 2025, from $94.9 million at the end of 2024 [13].
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity